Travere Therapeutics Inc.

Last updated September 27, 2026

Favorite this organization

Organization details

Legal name: Travere Therapeutics Inc.
Former names: Retrophin, Inc. Desert Gateway, Inc.
Ownership: Public
Status: Active
SIC code: 2834 — Pharmaceutical Preparations
Jurisdiction of incorporation: California
Headquarters city: SAN Diego
Headquarters state / province: California
Headquarters country: United States
Fiscal year end: December
Ticker symbol: TVTX
Primary stock exchange: Nasdaq

Identifiers

SEC CIK: 0001438533
EIN: 26-2383102

Board of directors

Follow this board

Brinkley Ruth Williams · Director
Since 2023
Eric M. Dube · Director · CHIEF EXECUTIVE OFFICER
Since 2023
Gary A. Lyons · Director
Since 2023
Jeffrey A. Meckler · Director
Since 2023
John A. Orwin · Director
Since 2023
Ron Squarer · Director
Since 2023
Roy D. Baynes · Director
Since 2023
Sandra Poole · Director
Since 2023
Suzanne Louise Bruhn · Director
Since 2023
Timothy Coughlin · Director Overboarded
Since 2023

Chief executives

Eric M. Dube · Chief Executive Officer

Dates unknown

Director election results

Annual meeting of May 19, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.

Board connections

9 of this board's directors also sit on 16 other boards.

Shared director Other board Same sector

ADC Therapeutics SA
via Ron Squarer and Timothy Coughlin
Natera Inc.
via Brinkley Ruth Williams and Roy D. Baynes
Aardvark Therapeutics Inc.
via Roy D. Baynes
AnaptysBio Inc.
via John A. Orwin
Definium Therapeutics Inc.
via Suzanne Louise Bruhn
Eledon Pharmaceuticals Inc.
via Gary A. Lyons
Fate Therapeutics Inc.
via Timothy Coughlin
First Tracks Biotherapeutics Inc.
via John A. Orwin
Indaptus Therapeutics Inc.
via Jeffrey A. Meckler
Neurocrine Biosciences Inc.
via Gary A. Lyons
Nurix Therapeutics Inc.
via Roy D. Baynes
OnKure Therapeutics Inc.
via Eric M. Dube
Pliant Therapeutics Inc.
via Suzanne Louise Bruhn
Rigel Pharmaceuticals Inc.
via Gary A. Lyons
Vir Biotechnology Inc.
via Timothy Coughlin
aTyr Pharma Inc.
via Timothy Coughlin

Insider trades

All notable trades →

From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.

Bought, last 12 months: $0; 0 purchases by 0 insiders
Sold, last 12 months: $104,242,400; 121 sales by 11 insiders

Date	Insider	Transaction	Shares	Price	Value
Sep 17, 2026	Eric M. Dube Director, Officer (CHIEF EXECUTIVE OFFICER)	Option exercise	+108,493	$23.34	$2,532,227
Sep 17, 2026	Eric M. Dube Director, Officer (CHIEF EXECUTIVE OFFICER)	Open-market sale	−101,691	$64.59	$6,567,876
Sep 17, 2026	Eric M. Dube Director, Officer (CHIEF EXECUTIVE OFFICER)	Open-market sale	−6,802	$64.95	$441,795
Sep 17, 2026	Heerma Peter Officer (EVP, CHIEF COMMERCIAL OFFICER)	Option exercise	+8,282	$22.40	$185,517
Sep 17, 2026	Heerma Peter Officer (EVP, CHIEF COMMERCIAL OFFICER)	Open-market sale	−8,282	$65.07	$538,917
Sep 16, 2026	Eric M. Dube Director, Officer (CHIEF EXECUTIVE OFFICER)	Option exercise	+195,841	$23.34	$4,570,929
Sep 16, 2026	Eric M. Dube Director, Officer (CHIEF EXECUTIVE OFFICER)	Open-market sale	−99,716	$63.26	$6,307,964
Sep 16, 2026	ROTE WILLIAM E. Officer (Chief Research Officer)	Option exercise	+350	$17.96	$6,286
Sep 16, 2026	Eric M. Dube Director, Officer (CHIEF EXECUTIVE OFFICER)	Open-market sale	−96,125	$63.64	$6,117,289
Sep 16, 2026	Heerma Peter Officer (EVP, CHIEF COMMERCIAL OFFICER)	Option exercise	+100,000	$11.25	$1,125,000
Sep 16, 2026	ROTE WILLIAM E. Officer (Chief Research Officer)	Option exercise	+55,000	$15.46	$850,300
Sep 16, 2026	Heerma Peter Officer (EVP, CHIEF COMMERCIAL OFFICER)	Option exercise	+55,000	$15.46	$850,300
Sep 16, 2026	ROTE WILLIAM E. Officer (Chief Research Officer)	Option exercise	+57,500	$26.88	$1,545,600
Sep 16, 2026	Heerma Peter Officer (EVP, CHIEF COMMERCIAL OFFICER)	Option exercise	+17,717	$26.88	$476,233
Sep 16, 2026	ROTE WILLIAM E. Officer (Chief Research Officer)	Open-market sale	−65,104	$63.12	$4,109,397

Reviews (0)

No reviews yet. Be the first to write one.